interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Fosaprepitant Dimeglumine

Generic competition · all medicines · read 12 November 2026

Is there a generic of Fosaprepitant Dimeglumine, and who makes it?

Fosaprepitant Dimeglumine appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 9 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 8.4 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Fosaprepitant Dimeglumine2 dosage-form groups in the Orange Book
9generic makers listed
  1. Fosaprepitant Dimeglumine appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 9 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 8.4 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Powder, Intravenous

Four or more generic makers listed

Brand listed as marketed: Emend, Fosaprepitant Dimeglumine and Navitrux. 9 generic makers with 9 generic products listed as marketed; the first generic approval is dated 9 June 2016.

20052010201520202025203009brand 2008Fresenius Kabi Usa Llc, first approval 9 June 2016Be Pharmaceuticals Ag, first approval 5 September 2019Msn Laboratories Private Ltd, first approval 5 September 2019Mylan Laboratories Ltd, first approval 5 September 2019Qilu Pharmaceutical Hainan Co Ltd, first approval 8 September 2020Dr Reddys Laboratories Ltd, first approval 9 December 2020Eugia Pharma Specialities Ltd, first approval 12 January 2021Chia Tai Tianqing Pharmaceutical Group Co Ltd, first approval 3 March 2021Aspiro Pharma Ltd, first approval 29 July 2021data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Fresenius Kabi Usa Llc9 June 20161
Be Pharmaceuticals Ag5 September 20191
Msn Laboratories Private Ltd5 September 20191
Mylan Laboratories Ltd5 September 20191
Qilu Pharmaceutical Hainan Co Ltd8 September 20201
Dr Reddys Laboratories Ltd9 December 20201
Eugia Pharma Specialities Ltd12 January 20211
Chia Tai Tianqing Pharmaceutical Group Co Ltd3 March 20211
Aspiro Pharma Ltd29 July 20211

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Intravenous

Brand listed, no generic listed as marketed

Brand listed as marketed: Focinvez. No generic is listed as marketed.

2020202520302035204001brand 2023data datePatent 12042504 listed to expire 11 January 2039Patent 11065265 listed to expire 11 January 2039
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 11 January 2039Patent 12042504 drug product
  • 11 January 2039Patent 11065265 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.